BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Data From Peregrine Pharmaceuticals, Inc. (PPHM)'s Phase II Bavituximab Second-Line Lung Cancer Trial to be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology


9/4/2012 9:21:54 AM

TUSTIN, CA--(Marketwire - September 04, 2012) -

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced it will be presenting data from its double-blind, placebo controlled, Phase II bavituximab trial in second-line non-small cell lung cancer at an upcoming plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology to be held at the Chicago Marriott Downtown Magnificent Mile in Chicago, Illinois from September 6-8, 2012. The late-breaking oral presentation will be held on September 7, 2012 at 1:40 PM CDT.

Oral Presentation Details:

Late-Breaking Plenary Presentation LBPL2

Title: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer (Top-line Results)

Speaker: David Gerber, M.D., University of Texas Southwestern Medical Center

Time: Friday, Sep 07, 2012, 1:40 PM - 1:50 PM CT

Authors: D. E. Gerber(1), M. Joppert(2), D. R. Spigel(3), D. P. Singh(4), D. Giorgadze(5), M. Shtivelband(6), O. V. Ponomarova(7), J. Shan(8), C. P. Belani(9)

1) Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.; 2) Florida Cancer Specialists, Ft. Meyers, FL.; 3) Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN.; 4) Department of Radiotherapy & Clinical Oncology, S.M.S. Medical College & Attached Hospitals, Jaipur, India.; 5) Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia.; 6) Ironwood Cancer and Research Centers, Chandler, AZ.; 7) RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kiev, Ukraine.; 8) Peregrine Pharmaceuticals, Inc., Tustin, CA.; 9) Penn State Hershey Cancer Institute, Hershey, PA.

Audio Webcast
In conjunction with Dr. Gerber's presentation in Chicago, Peregrine will post an audio webcast and slide deck to Peregrine's website. The pre-recorded webcast will be hosted by Joseph Shan, vice president of clinical and regulatory affairs. Access to the audio and corresponding slides can be found on Peregrine's website.

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company's PS technology platform and is currently being tested in eight clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and five investigator-sponsored trials (ISTs) in additional oncology indications and treatment combinations.

PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in oncology with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.


Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES